Imaging assessment of tumor response: past, present and future

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Miller AB, Hoogstraten B, Staquet M et al.: Reporting results of cancer treatment. Cancer47,207–214 (1981).
  Medline CASGoogle Scholar
• 2  Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J. Natl Cancer Inst.92,205–216 (2000).▪ The original Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
  Medline CASGoogle Scholar
• 3  Husband JE, Schwartz LH, Spencer J et al.: Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society. Br. J. Cancer90,2256–2260 (2004).
  Medline CASGoogle Scholar
• 4  Benjamin RS, Choi H, Macapinlac HA et al.: We should desist using RECIST, at least in GIST. J. Clin. Oncol.25,1760–1764 (2007).
  MedlineGoogle Scholar
• 5  Choi H: Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr. Oncol. Rep.7,307–311 (2005).
  MedlineGoogle Scholar
• 6  Barnacle AM, McHugh K: Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr. Blood Cancer46,127–134 (2006).
  Medline CASGoogle Scholar
• 7  Nowak AK: CT, RECIST, and malignant pleural mesothelioma. Lung Cancer49(Suppl. 1),S37–S40 (2005).
  MedlineGoogle Scholar
• 8  Eisenhauer EA, Therasse P, Bogaerts J et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45,228–247 (2009).▪▪ The key article describing the modified RECIST 1.1 guidelines.
  Medline CASGoogle Scholar
• 9  Bogaerts J, Ford R, Sargent D et al.: Individual patient data analysis to assess modifications to the RECIST criteria. Eur. J. Cancer45,48–60 (2009).
  MedlineGoogle Scholar
• 10  Schwartz LH, Bogaerts J, Ford R et al.: Evaluation of lymph nodes with RECIST 1.1. Eur. J. Cancer45,261–267 (2009).
  Medline CASGoogle Scholar
• 11  Hutchings M, Barrington SF: PET/CT for therapy response assessment in lymphoma. J. Nucl. Med.50,S21–S30 (2009).
  Google Scholar
• 12  Hampson FA, Shaw AS: Response assessment in lymphoma. Clin. Radiol.63,125–135 (2008).
  Medline CASGoogle Scholar
• 13  Kim KW, Lee JM, Choi BI: Assessment of the treatment response of HCC. Abdom. Imaging DOI: 10.1007/s00261-011-9683-3 (2011) (Epub ahead of print).
  Google Scholar
• 14  Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis.30,52–60 (2010).
  Medline CASGoogle Scholar
• 15  Choi SH, Moon WK: Contrast-enhanced MR imaging of lymph nodes in cancer patients. Korean J. Radiol.11,383–394 (2010).
  MedlineGoogle Scholar
• 16  Nishino M, Jagannathan JP, Ramaiya N et al.: Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am. J. Roentgenol.195,281–289 (2010).▪ A useful summary on the changes in RECIST 1.1.
  MedlineGoogle Scholar
• 17  Weber WA: Assessing tumor response to therapy. J. Nucl. Med.50(Suppl. 1),S1–S10 (2009).
  Medline CASGoogle Scholar
• 18  Zee YK, O’Connor JP, Parker GJ et al.: Imaging angiogenesis of genitourinary tumors. Nat. Rev. Urol.7,69–82 (2010).
  MedlineGoogle Scholar
• 19  Choi H, Charnsangavej C, de Castro Faria S et al.: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am. J. Roentgenol.183,1619–1628 (2004).
  MedlineGoogle Scholar
• 20  van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al.: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br. J. Cancer102,803–809 (2010).
  Medline CASGoogle Scholar
• 21  Gill RR, Gerbaudo VH, Sugarbaker DJ et al.: Current trends in radiologic management of malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg.21,111–120 (2009).
  MedlineGoogle Scholar
• 22  Choi H: Response evaluation of gastrointestinal stromal tumors. Oncologist13,4–7 (2008).
  MedlineGoogle Scholar
• 23  van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al.: Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol.5,95–112 (2010).
  MedlineGoogle Scholar
• 24  Smith AD, Lieber ML, Shah SN: Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Am. J. Roentgenol.194,157–165 (2010).
  MedlineGoogle Scholar
• 25  Dudeck O, Zeile M, Reichardt P, Pink D: Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann. Oncol. DOI: 10.1093/annonc/mdq696 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 26  Eradat J, Abtin F, Gutierrez A, Suh R: Evaluation of treatment response after nonoperative therapy for early-stage non-small cell lung carcinoma. Cancer J.17,38–48 (2011).
  MedlineGoogle Scholar
• 27  Lee HY, Lee KS, Ahn MJ et al.: New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer DOI: 10.1016/j.lungcan.2010.10.019 (2010) (Epub ahead of print).
  Google Scholar
• 28  Lee HY, Lee KS, Hwang HS et al.: Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J. Radiol.11,618–626 (2010).
  MedlineGoogle Scholar
• 29  Padhani AR, Khan AA: Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol.5,39–52 (2010).
  MedlineGoogle Scholar
• 30  Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B: Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. Am. J. Roentgenol.193,1044–1052 (2009).
  MedlineGoogle Scholar
• 31  González Hernando C, Esteban L, Cañas T et al.: The role of magnetic resonance imaging in oncology. Clin. Transl. Oncol.12,606–613 (2010).▪ A comprehensive article focusing on different aspects of MRI, including strengths and weaknesses.
  MedlineGoogle Scholar
• 32  Fernández-Guinea O, Andicoechea A, González LO et al.: Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer. BMC Cancer10,8 (2010).
  MedlineGoogle Scholar
• 33  Matsuoka S, Hunsaker AR, Gill RR et al.: Functional MR imaging of the lung. Magn. Reson. Imaging Clin. N. Am.16,275–289 (2008).
  MedlineGoogle Scholar
• 34  Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO: Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br. J. Cancer102,1–7 (2010).
  Medline CASGoogle Scholar
• 35  Dhermain FG, Hau P, Lanfermann H et al.: Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol.9,906–920 (2010).
  MedlineGoogle Scholar
• 36  Glunde K, Bhujwalla ZM: Metabolic tumor imaging using magnetic resonance spectroscopy. Semin. Oncol.38,26–41 (2011).
  MedlineGoogle Scholar
• 37  Koh DM, Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. Am. J. Roentgenol.188,1622–1635 (2007).
  MedlineGoogle Scholar
• 38  Arlinghaus LR, Li X, Levy M et al.: Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J. Oncol. (2010) PII: 919620 (2010).
  Google Scholar
• 39  Afaq A, Andreou A, Koh DM: Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging10,S179–S88 (2010).
  MedlineGoogle Scholar
• 40  Fenchel M, Konaktchieva M, Weisel K et al.: Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility study. Acad. Radiol.17,1326–1333 (2010).
  MedlineGoogle Scholar
• 41  Koh DM, Blackledge M, Collins DJ et al.: Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre Phase I clinical trial. Eur. Radiol.19,2728–2738 (2009).
  MedlineGoogle Scholar
• 42  Jain R: Perfusion CT imaging of brain tumors: an overview. Am. J. Neuroradiol. DOI: 10.3174/ajnr.A2263 (2010) (Epub ahead of print).
  Google Scholar
• 43  Pollard RE, Larson RF: Dynamic contrast-enhanced computed tomography for the quantification of tumor response to vasoactive agents in a rat tumor model: preliminary results. Contrast Media Mol. Imaging6(1),28–34 (2011).
  Medline CASGoogle Scholar
• 44  Choi SH, Chung JW, Kim HC et al.: The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest. Radiol.45,427–436 (2010).
  MedlineGoogle Scholar
• 45  Hegenscheid K, Behrendt N, Rosenberg C et al.: Assessing early vascular changes and treatment response after laser-induced thermotherapy of pulmonary metastases with perfusion CT: initial experience. Am. J. Roentgenol.194,1116–1123 (2010).
  MedlineGoogle Scholar
• 46  Squillaci E, Manenti G, Cicciò C et al.: Perfusion-CT monitoring of cryo-ablated renal cells tumors. J. Exp. Clin. Cancer Res.28,138 (2009).
  MedlineGoogle Scholar
• 47  Wu GY, Ghimire P: Perfusion computed tomography in colorectal cancer: protocols, clinical applications and emerging trends. World J. Gastroenterol.15,3228–3231 (2009).
  MedlineGoogle Scholar
• 48  Goh V, Dattani M, Farwell J et al.: Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. Eur. Radiol.21(5),974–981 (2010).
  MedlineGoogle Scholar
• 49  Bellomi M, Viotti S, Preda L, D’Andrea G, Bonello L, Petralia G: Perfusion CT in solid body-tumours. Part II: clinical applications and future development. Radiol. Med.115,858–874 (2010).
  Medline CASGoogle Scholar
• 50  Kong WT, Zhang WW, Guo HQ et al.: Application of contrast-enhanced ultrasonography after radiofrequency ablation for renal cell carcinoma: is it sufficient for assessment of therapeutic response? Abdom. Imaging DOI: 10.1007/s00261-010-9665-x (2010) (Epub ahead of print).
  Google Scholar
• 51  Lassau N, Koscielny S, Chami L et al.: Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification – preliminary results. Radiology258(1),291–300 (2011).
  MedlineGoogle Scholar
• 52  Lassau N, Chami L, Koscielny S et al.: Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest. New Drugs DOI: 10.1007/s10637-010-9592-2 (2010) (Epub ahead of print).
  Google Scholar
• 53  Lassau N, Koscielny S, Albiges L et al.: Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin. Cancer Res.16,1216–1225 (2010).
  Medline CASGoogle Scholar
• 54  Lassau N, Chami L, Chebil M et al.: Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov. Med.11,18–24 (2011).
  MedlineGoogle Scholar
• 55  Wahl RL, Jacene H, Kasamon Y et al.: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med.50,S122–S150 (2009).▪ Detailed description of potential response assessment criteria for PET.
  Medline CASGoogle Scholar
• 56  Zaidi H, Montandon ML, Alavi A: The clinical role of fusion imaging using PET, CT, and MR imaging. Magn. Reson. Imaging Clin. N. Am.18,133–149 (2010).
  MedlineGoogle Scholar
• 57  Marten K, Auer F, Schmidt S, Kohl G, Rummey EJ, Engelke C: Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur. Radiol.16,781–790 (2006).
  MedlineGoogle Scholar
• 58  Keil S, Behrendt FF, Stanzel S et al.: Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semiautomated and manual measurement of RECIST and WHO criteria. Eur. Radiol.18,2456–2465 (2008).
  MedlineGoogle Scholar
• 59  Fabel M, von Tengg-Kobligk H, Giesel FL et al.: Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV – a feasibility study. Eur. Radiol.18,1114–1122 (2008).
  Medline CASGoogle Scholar
• 60  Ertl-Wagner BB, Blume JD, Peck D et al.: Reliability of tumor volume estimation from MR images in patients with malignant glioma. Results from the American College of Radiology Imaging Network (ACRIN) 6662 trial. Eur. Radiol.19,599–609 (2009).
  MedlineGoogle Scholar
• 61  van Persijn van Meerten EL, Gelderblom H, Bloem JL: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur. Radiol.20,1456–1467 (2010).
  MedlineGoogle Scholar